MICA · CARE LEARNING NOTES
Observe, keep care safe and communicate
IV immunoglobulins can cause immediate reactions and delayed complications. Previous good tolerability does not remove the risk. This adult guide structures observations to share with the prescriber and biological product traceability.
Identify Privigen and its specific features
The reference SmPC is for Privigen 100 mg/mL human normal immunoglobulin solution for infusion, CSL Behring, UK. Check brand, concentration, presentation, route, batch and prescription. Subcutaneous immunoglobulins and other brands must not be treated as this product. Privigen contains proline: known hyperprolinaemia is a contraindication in this SmPC. Conformity of the product actually available in Algeria requires local verification.
[1]Gather individual risk information
Check previous reactions, selective IgA deficiency with anti-IgA antibodies, thrombosis risk, immobility, renal impairment and nephrotoxic medicines. Report a brand change, first exposure or long treatment gap. Check the medical hydration and renal monitoring plan without imposing uniform fluid intake on a patient with heart failure. The prescriber tailors investigations to the indication and individual risks.
[1][2][3]Recognise immediate and delayed complications
Observe during and after infusion according to the validated plan. Dyspnoea, chest pain, hypotension or a new neurological deficit require urgent escalation; a severe reaction during administration requires interruption of the suspected product and the emergency protocol. After treatment, severe headache with neck stiffness, dark urine, jaundice, pallor or reduced urine output warrant prompt assessment. Possible aseptic meningitis does not exclude infection requiring investigation.
[1][2][3]Changing product or a long treatment interruption may change monitoring precautions. Check the plan for the product actually administered. Severe headache, chest pain, neurological deficit, breathlessness or reduced urine output require prompt assessment, including after the session. Patients need a contact for delayed symptoms.
- Record the brand and batch number for traceability.
Link follow-up to the administered product
Record the exact name and batch number, times, tolerability and medical decisions. Provide understandable instructions about delayed symptoms and the service contact. Restart after a reaction and any product change require documented medical and pharmacy decisions; comparing concentrations alone is insufficient to ensure safety.
[1][2][3]A learning situation
FICTIONAL SITUATION · REFLECTION WITHOUT A SCORE
Fictional situation: the day after an infusion, a patient calls with severe headache, photophobia and neck stiffness.
Can she be reassured that this is a usual reaction?
References and scope
- Privigen 100 mg/ml solution for infusion — SmPC (UK) ↗
- Privigen 100 mg/ml solution for infusion — Patient Information Leaflet (UK) ↗
- Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) — Rev. 6 ↗
Original documentary teaching summary for adult care. Procedures and medicines depend on professional competence, prescription and institutional procedures. International references do not establish an Algerian protocol. Independent human scientific review remains to be confirmed.